CIK 0001370053 · Non-accelerated filer<br>Smaller reporting company
ANAPTYSBIO, INC
Sign in to watch- Ticker
- ANAB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 203828755
- Phone
- 858-362-6295
- Business address
- 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA, 92121
- Former names
- ANAPTYSBIO INC, ANAPTYS BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $249,372
- in 1 filing, $249K under 10b5-1 plans
Net −$249,372. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-30 | Schmid John P. Director | Sale | −7,527 | $56.70 | $427K | 32,144 |
| 2026-03-30 | Schmid John P. Director | Sale | −522 | $57.40 | $30K | 31,622 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −510 | $56.61 | $29K | 513,134 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −2,570 | $57.91 | $149K | 510,564 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −3,662 | $58.62 | $215K | 506,902 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −490 | $59.62 | $29K | 506,412 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −550 | $60.63 | $33K | 505,862 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −1,012 | $62.15 | $63K | 504,850 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −2,592 | $63.35 | $164K | 502,258 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −3,155 | $64.19 | $203K | 499,103 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −3,038 | $65.20 | $198K | 496,065 |
| 2026-03-27 | Faga Daniel President, CEO | Sale | −100 | $65.99 | $7K | 495,965 |
| 2026-03-25 | Faga Daniel President, CEO | Grant or award | +34,300 | 513,644 | ||
| 2026-03-12 | Lizzul Paul F. Chief Medical Officer | Grant or award · Performance Stock Units | +16,667 | 16,667 | ||
| 2026-03-12 | Faga Daniel President, CEO | Grant or award · Performance Stock Units | +53,334 | 53,334 | ||
| 2026-02-11 | LOUMEAU ERIC J CHIEF LEGAL OFFICER | Option exercise 10b5-1 | +10,000 | $29.70 | $297K | 22,835 |
| 2026-02-11 | LOUMEAU ERIC J CHIEF LEGAL OFFICER | Sale 10b5-1 | −10,000 | $54.00 | $540K | 12,835 |
| 2026-02-11 | LOUMEAU ERIC J CHIEF LEGAL OFFICER | Option exercise · Employee Stock Option (right to buy) 10b5-1 | −10,000 | 35,000 | ||
| 2026-01-15 | Marquet Magda Director | Option exercise | +11,000 | $26.11 | $287K | 20,930 |
| 2026-01-15 | Marquet Magda Director | Sale | −9,290 | $48.12 | $447K | 11,640 |
Page 5 of 17 · 339 trades